Results 161 to 170 of about 7,608 (177)

Tocilizumab versus Rituximab in Patients with Moderate to Severe Steroid-resistant Graves’ Orbitopathy

Ocular Immunology and Inflammation, 2022
Vincent Borderie, Arsene Mekinian
exaly  

Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study

Journal of Endocrinological Investigation, 2020
Luigi Bartalena, George J Kahaly, Ilaria Muller   +2 more
exaly  

Polydatin attenuates orbital oxidative stress in Graves’ orbitopathy through the NRF2 pathway

Chemico-Biological Interactions, 2020
Hong Li
exaly  

Natural history of graves’ orbitopathy after treatment

Endocrine, 2016
Marco Nardi, Paolo Vitti, Claudio Marcocci   +2 more
exaly  

Glucocorticoids in Graves’ orbitopathy: mechanisms of action and clinical application

Therapeutic Advances in Endocrinology and Metabolism, 2020
George J Kahaly
exaly  

Color Doppler imaging of the superior ophthalmic vein in different clinical forms of Graves’ orbitopathy

Japanese Journal of Ophthalmology, 2008
Mario Luiz Ribeiro Monteiro
exaly  

Lower Eyelid Contour in Graves Orbitopathy

Current Eye Research, 2019
Denny M Garcia
exaly  

Late reactivation of thyroid orbitopathy

Clinical and Experimental Ophthalmology, 2004
Dinesh Selva
exaly  

Sight‐threatening Graves’ orbitopathy: Twenty years’ experience of a multidisciplinary thyroid‐eye outpatient clinic

Clinical Endocrinology, 2019
Philippe J Caron
exaly  

Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study

Lancet, The, 2000
exaly